{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:53Z","timestamp":1791404153886,"version":"4.3.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40259-022-00534-w","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:03:49Z","timestamp":1653041029000},"page":"393-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects"],"prefix":"10.1007","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct04411550","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jingjing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihe","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-3798","authenticated-orcid":false,"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"534_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102339","volume":"104","author":"D Trapani","year":"2022","unstructured":"Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, et al. Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022;104: 102339. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102339.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"534_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15585\/mmwr.mm7102a2","volume":"71","author":"T Ellington","year":"2022","unstructured":"Ellington T, Miller J, Henley S, Wilson R, Wu M, Richardson L. Trends in breast cancer incidence, by race, ethnicity, and age among women aged \u226520 years\u2014United States, 1999\u20132018. MMWR Morb Mortal Wkly Rep. 2022;71(2):43\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7102a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"534_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/gco.0000000000000762","volume":"34","author":"N McAndrew","year":"2022","unstructured":"McAndrew N. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what\u2019s to know in 2021. Curr Opin Obstet Gynecol. 2022;34(1):41\u20135. https:\/\/doi.org\/10.1097\/gco.0000000000000762.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"7","key":"534_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf D, Han H, Du L, Wallace A, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-98.e5. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.009.","journal-title":"Cancer Cell"},{"key":"534_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3032","author":"Y Lu","year":"2021","unstructured":"Lu Y, Im S, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy vs endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3032.","journal-title":"Clin Cancer Res"},{"key":"534_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246358","author":"A Beddok","year":"2021","unstructured":"Beddok A, Cottu P, Fourquet A, Kirova Y. Combination of modern radiotherapy and new targeted treatments for breast cancer management. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13246358.","journal-title":"Cancers"},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","volume":"152","author":"J O'Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.047.","journal-title":"Eur J Cancer"},{"key":"534_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194790","author":"A Aboudaram","year":"2021","unstructured":"Aboudaram A, Loap P, Loirat D, Dhia S, Cao K, Fourquet A, et al. Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13194790.","journal-title":"Cancers"},{"issue":"10286","key":"534_CR9","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/s0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(20)32381-3.","journal-title":"Lancet"},{"key":"534_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.breast.2017.01.010","volume":"32","author":"C Jackisch","year":"2017","unstructured":"Jackisch C, Lammers P, Jacobs I. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast. 2017;32:199\u2013216. https:\/\/doi.org\/10.1016\/j.breast.2017.01.010.","journal-title":"Breast"},{"issue":"6","key":"534_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40259-019-00381-2","volume":"33","author":"K Paek","year":"2019","unstructured":"Paek K, Kim G, Ahn S, Lim J, Jung D, Kim S, et al. Assessment of the molecular mechanism of action of SB3, a trastuzumab biosimilar. BioDrugs. 2019;33(6):661\u201371. https:\/\/doi.org\/10.1007\/s40259-019-00381-2.","journal-title":"BioDrugs"},{"issue":"1","key":"534_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","volume":"8","author":"TWJ Huizinga","year":"2021","unstructured":"Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8(1):41\u201361. https:\/\/doi.org\/10.1007\/s40744-020-00259-8.","journal-title":"Rheumatol Ther."},{"key":"534_CR13","doi-asserted-by":"publisher","first-page":"6262383","DOI":"10.1155\/2016\/6262383","volume":"2016","author":"M Partridge","year":"2016","unstructured":"Partridge M, Purushothama S, Elango C, Lu Y. Emerging technologies and generic assays for the detection of anti-drug antibodies. J Immunol Res. 2016;2016:6262383. https:\/\/doi.org\/10.1155\/2016\/6262383.","journal-title":"J Immunol Res"},{"issue":"1","key":"534_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/nyas.14522","volume":"1491","author":"H Kang","year":"2021","unstructured":"Kang H, Thorpe R, Knezevic I, Casas Levano M, Chilufya M, Chirachanakul P, et al. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci. 2021;1491(1):42\u201359. https:\/\/doi.org\/10.1111\/nyas.14522.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"534_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00280-021-04334-x","volume":"88","author":"V Hanes","year":"2021","unstructured":"Hanes V, Chow V, Stewart T, Puri A. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects. Cancer Chemother Pharmacol. 2021;88(5):879\u201386. https:\/\/doi.org\/10.1007\/s00280-021-04334-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"534_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.660541","volume":"12","author":"Y Cui","year":"2021","unstructured":"Cui Y, Cui D, Ren X, Chen X, Liu G, Liu Z, et al. Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta\u00ae in Healthy Chinese Male Volunteers. Front Pharmacol. 2021;12: 660541. https:\/\/doi.org\/10.3389\/fphar.2021.660541.","journal-title":"Front Pharmacol"},{"issue":"2","key":"534_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/14712598.2021.1894121","volume":"22","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu T, Wu M, Wei H, Li C, Li X, et al. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men. Expert Opin Biol Ther. 2022;22(2):179\u201386. https:\/\/doi.org\/10.1080\/14712598.2021.1894121.","journal-title":"Expert Opin Biol Ther"},{"key":"534_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-2827","author":"J Zhang","year":"2021","unstructured":"Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, et al. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I study. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-2827.","journal-title":"Clin Cancer Res"},{"key":"534_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1988567","author":"G Liu","year":"2021","unstructured":"Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, et al. A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety and tolerance of pertuzumab injection and Perjeta\u00ae in healthy Chinese male subjects. Expert Opin Biol Ther. 2021. https:\/\/doi.org\/10.1080\/14712598.2021.1988567.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"534_CR20","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.Ccr-18-3997","volume":"25","author":"T Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab T, Wesolowski R, Ahn D, Wu C, Mortazavi A, Lustberg M, et al. Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors. Clin Cancer Res. 2019;25(12):3495\u2013507. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3997.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"534_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s10637-019-00890-5","volume":"38","author":"K Inoue","year":"2020","unstructured":"Inoue K, Takahashi M, Mukai H, Yamanaka T, Egawa C, Sakata Y, et al. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Investig New Drugs. 2020;38(5):1540\u20139. https:\/\/doi.org\/10.1007\/s10637-019-00890-5.","journal-title":"Investig New Drugs"},{"issue":"11","key":"534_CR22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","volume":"3","author":"M Alhussein","year":"2021","unstructured":"Alhussein M, Mokbel A, Cosman T, Aghel N, Yang E, Mukherjee S, et al. Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. CJC Open. 2021;3(11):1372\u201382. https:\/\/doi.org\/10.1016\/j.cjco.2021.06.019.","journal-title":"CJC Open."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:05:28Z","timestamp":1653804328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00534-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"13 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Shanghai Henlius Biotech, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Guilan Sun, Liang Zhou, Qingyu Wang, and Jun Zhu are employees of Shanghai Henlius Biotech, Inc. All other authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Hefei, China) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed consent before undergoing any study-specific procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Data are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The manuscript was developed under the primary guidance of WH and FL. Material preparation, data collection, and analysis were performed by\u00a0JY, LL, QL, QZ, GS, LZ, QW, and JZ. All authors reviewed and provided comments on the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}